Curi RMB Capital LLC Boosts Holdings in Omnicell, Inc. (NASDAQ:OMCL)

Curi RMB Capital LLC raised its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 0.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 88,815 shares of the company’s stock after purchasing an additional 651 shares during the period. Curi RMB Capital LLC’s holdings in Omnicell were worth $3,872,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of the business. Nisa Investment Advisors LLC raised its position in shares of Omnicell by 248.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 1,402 shares of the company’s stock worth $38,000 after purchasing an additional 1,000 shares during the last quarter. GAMMA Investing LLC lifted its position in shares of Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock valued at $55,000 after acquiring an additional 553 shares in the last quarter. EntryPoint Capital LLC boosted its stake in shares of Omnicell by 121.2% during the first quarter. EntryPoint Capital LLC now owns 2,455 shares of the company’s stock valued at $72,000 after acquiring an additional 1,345 shares during the last quarter. CWM LLC increased its position in Omnicell by 68.2% during the 2nd quarter. CWM LLC now owns 3,048 shares of the company’s stock worth $83,000 after purchasing an additional 1,236 shares in the last quarter. Finally, 1620 Investment Advisors Inc. raised its stake in Omnicell by 230.1% in the 3rd quarter. 1620 Investment Advisors Inc. now owns 2,212 shares of the company’s stock valued at $96,000 after purchasing an additional 1,542 shares during the last quarter. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on the stock. Craig Hallum raised their price target on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Wells Fargo & Company lifted their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a research note on Monday, October 14th. Bank of America reiterated a “neutral” rating and issued a $57.00 price target (up from $44.00) on shares of Omnicell in a report on Thursday, October 31st. Barclays raised their price objective on Omnicell from $39.00 to $58.00 and gave the stock an “equal weight” rating in a report on Thursday, October 31st. Finally, StockNews.com upgraded Omnicell from a “hold” rating to a “buy” rating in a research note on Saturday, October 19th. Four analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $50.83.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $46.60 on Friday. The firm has a fifty day moving average of $44.15 and a 200-day moving average of $36.63. Omnicell, Inc. has a 52-week low of $25.12 and a 52-week high of $55.74.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.